Coronavirus treatments

From Conservapedia
Jump to: navigation, search

Coronavirus treatments focuses on preventing a cytokine storm which causes deadly replication of the infection within the body by day 6 of the disease progression. The replication then overpowers the body and causes long-term illness, even death. If coronavirus is stopped upon exposure or very early in the disease progression, then long-term harm and death can often be avoided.

Treatment options include hydroxychloroquine, which requires a prescription, and zinc, which does not. These are inexpensive. If prescriptions are unavailable, then some recommend the over-the-counter quercetin medication and zinc, which can be purchased in vitamin stores and online without a prescription.

Treatments in New York

See also: Vladimir Zelenko's coronavirus treatment and Vladimir Zelenko

There is a report that COVID-19 cases in New York State are being treated effectively by the following combination of medications and zinc sulfate:

(1) Hydroxychloroquine 200mg twice a day for 5 days
(2) Azithromycin 500mg once a day for 5 days
(3) Zinc sulfate 220mg once a day for 5 days (this is equivalent to 50mg of elemental zinc as commonly sold like a vitamin)

Sodium Ascorbate

High dose intravenous sodium ascorbate is the number one secret of the pharmaceutical industry, because if it became widely known it would make the majority of their trillion dollar industry obsolete. It has been used for over 70 years on a range of conditions with a high level of success. To rapidly treat a viral condition like COVID-19, the infusion needs to be in the range of 50 to 100 grams. Ideally 1 gram per kg body weight. For COVID-19 two treatments on consecutive days is usually adequate. It has been used by Dr Richard Cheng from Shanghai on COVID-19 patients with a 100% success rate. Scientific references: List of news releases:

Nursing homes

Without use of hydroxychloroquine, 37 people died in connection with a single nursing home in Washington State.[1] With use of hydroxychloroquine, only one died out of 87 people (56 out of 135 residents, plus 31 of the staff) at "The Resort" nursing home in Texas who tested positive for COVID-19.[2]

Success in Florida

A patient recovered in a hospital in Florida from COVID-19 as the New York Post reported:[3]

After more than a week, doctors told him there was nothing more they could do and, on Friday evening, Giardinieri said goodbye to his wife and three children.

“I was at the point where I was barely able to speak and breathing was very challenging,” Giardinieri said. “I really thought my end was there.”

Then, a friend sent him a recent article about hydroxychloroquine, an over-the-counter drug that’s been used to treat malaria for decades and auto-immune diseases like lupus. ... Giardinieri said he contacted an infectious disease doctor about the drug.

“He gave me all the reasons why I would probably not want to try it because there are no trials, there’s no testing, it was not something that was approved,” said Giardinieri.

“And I said, ‘look I don’t know if I’m going to make it until the morning,’ because at that point I really thought I was coming to the end because I couldn’t breathe anymore,” Giardinieri continued.

“He agreed and authorized the use of it and 30 minutes later the nurse gave it to me.”

After about an hour on an IV with the medicine, Giardinieri said it felt like his heart was beating out of his chest and, about two hours later, he had another episode where he couldn’t breathe.

He says he was given Benadryl and some other drugs and that when he woke up around 4:45 a.m., it was “like nothing ever happened.”

He’s since had no fever or pain and can breathe again. Giardinieri said doctors believe the episodes he experienced were not a reaction to the medicine but his body fighting off the virus.

New Studies

A study on the use of chloroquine against COVID-19, by Devaux, Rolain, Colson and Raoult.[4]

Success with 78 out of 80 patients in France.[5]

French study

French researchers using a small sample size found a high cure rate by using a combination of hydroxychloroquine and azithromycin (an antibiotic):[6]

Six patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms.

Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination.

An article in Nature also suggests the potential for off-label use of hydroxychloroquine, which was used long ago for malaria and was first synthesized in 1946, to treat coronavirus (SARS-CoV-2):[7]

[O]ur results show that HCQ [Hydroxychloroquine] can efficiently inhibit SARS-CoV-2 infection in vitro. In combination with its anti-inflammatory function, we predict that the drug has a good potential to combat the disease.

Communist China has been developing treatment guidelines, now in their sixth edition, faster than the United States has. The Guidelines for the Diagnosis and Treatment of COVID-19 (6th Ed.), which is published by the National Health Commission of communist China, lists chloroquine (CQ) phosphate as a potentially even better drug than HCQ due to a lower cost, more potent effect, and wider availability.[7]


Azithromycin is traditionally used to treat bacterial rather than viral infections, and hence would not be expected to be effective if prescribed alone to treat coronavirus (COVID-19):[8]

Azithromycin is used to treat certain bacterial infections, such as bronchitis; pneumonia; sexually transmitted diseases (STD); and infections of the ears, lungs, sinuses, skin, throat, and reproductive organs. Azithromycin also is used to treat or prevent disseminated Mycobacterium avium complex (MAC) infection [a type of lung infection that often affects people with human immunodeficiency virus (HIV)]. Azithromycin is in a class of medications called macrolide antibiotics. It works by stopping the growth of bacteria.

Azithromycin is reportedly effective in reducing the viral load, and in combating lung infections which are associated with COVID-19.[9]

Off-Label Use and the FDA

The FDA sharply impedes the development of new medications in the United States, while communist China allows more freedom in rapidly developing and using new treatments. But the FDA is not authorized to make decisions about the practice of medicine, and thus it is generally allowed for a physician to use an old medication for a new purpose if it has been previously approved without limitation by the FDA. This is known as "off-label" use of a drug.

"From the FDA perspective, once the FDA approves a drug, healthcare providers generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient."[10]

As explained by the website for the National Institutes of Health:[11]

Off-label drug use involves prescribing medications for indications, or using a dosage or dosage form, that have not been approved by the US Food and Drug Administration. Since the Food and Drug Administration does not regulate the practice of medicine, OLDU has become common. It occurs in every specialty of medicine ....


A study published in June 2020 showed a remarkable 35% reduction in mortality from COVID-19 upon administration of dexamethasone:[12]

In patients who needed to be on a ventilator, dexamethasone reduced the death rate by 35%, meaning that doctors would prevent one death by treating eight ventilated patients. In those who needed oxygen but were not ventilated, the death rate was reduced 20%, meaning doctors would need to treat 25 patients to save one life. Both results were statistically significant.

See also


  6. Gautret et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial. International Journal of Antimicrobial Agents – In Press 17 March 2020 – DOI : 10.1016/j.ijantimicag.2020.105949 [1]
  7. 7.0 7.1